Perinatal Substance Abuse: At the Clinical Crossroads of Policy and Practice.

Samuel J. House,J. Coker,Z. Stowe

DOI: https://doi.org/10.1176/APPI.AJP.2015.15081104

IF: 17.7

2016-11-01

American Journal of Psychiatry

Abstract:Although much of the focus in treatment of psychiatric illness in pregnancy has been onmood disorders, the prevalence of substance abuse rivals that of major depressive disorder during pregnancy (1). A survey of drug use and health indicated that 5.4% of pregnant women ages 15–44 used illicit drugs (marijuana, cocaine, heroin, hallucinogens, inhalants, “Ms.A,” a 27-year-old, single, college-educated, primigravid Caucasian woman, was hospitalized after she crashed in an all-terrain vehicle and suffered a liver laceration. A urine drug screen detected benzodiazepines, methamphetamine, andmarijuana. At her initial prenatal appointment 5 weeks later, she reported taking alprazolam on several occasions for anxiety but declined psychiatric referral. Over several weeks, she visited the emergency department several times to obtain opioid medications for pain. At 21weeks’ gestation,Ms. A presented to the emergency department requesting detoxification from opioids. She reported that shewas currently taking approximately 60mgof oxycodonedaily andhadanextensivehistoryof prescription medication abuse, obtained frommultiple providers as well as from friends and family. She had previously participated in methadone and buprenorphine maintenance programs. Ms. A had a history of anxiety and depression resulting in two psychiatric hospitalizations. She had been treated with alprazolam,fluoxetine, and bupropion, but she discontinued these medications, as she “felt better off of them.” Physical examination, review of systems, and laboratory results were unremarkable. The examining physician discussed treatment options, including inpatient detoxification or stabilization and enrollment in an opioid maintenance program. After providing informed consent, Ms. A opted for enrollment in the buprenorphine maintenance program within the Women’s Mental Health Program (WMHP). The WMHP provides comprehensive treatment for neuropsychiatric illnesses during the perinatal period, with specialized services for substance use, including licit substances such as tobacco andalcohol.Ms.Adenieduseof tobaccoandreported that shehaddiscontinueduseof alcoholwhenshe learned that she was pregnant. On admission, her physician started her on buprenorphine, and her dosage was adjusted to 8 mg/day by the time of discharge. State laws regarding perinatal substance use were reviewed with the patient. Consistent with state law addressing drug testing in the postpartum period, no report to the Department of Human Services (DHS) was made during admission.